, Volume 65, Issue 9, pp 1292–1294 | Cite as

Infliximab in Ankylosing Spondylitis

A Viewpoint by Jürgen Braun
  • Jürgen Braun
Adis Drug Profile Guest Commentary


Infliximab Ankylose Spondylitis Etanercept Adalimumab Spondylitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Haibel H, Brandt HC, Rudwaleit M, et al. Preliminary results of an open-label, 12 week trial of adalimumab in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2004; 64 Suppl. 1: 399Google Scholar
  2. 2.
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003 Feb 13; 348(7): 601–8PubMedCrossRefGoogle Scholar
  3. 3.
    Baraliakos X, Listing J, Rudwaleit M, et al. Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor-α antibody infliximab. Ann Rheum Dis. Epub 2005 Mar 18Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Jürgen Braun
    • 1
  1. 1.Rheumazentrum RuhrgebietRuhr University BochumHerneGermany

Personalised recommendations